{
    "nct_id": "NCT05999968",
    "official_title": "A Phase 1b Study of Abemaciclib Plus Darolutamide in Men With Metastatic Castration-Resistant Prostate Cancer",
    "inclusion_criteria": "* Histologically confirmed adenocarcinoma of the prostate.\n* Metastatic castration-resistant prostate cancer evidenced by:\n\n  * Prostate-specific antigen (PSA) or radiographic progression despite castrate levels of testosterone\n  * At least 1 bone metastasis on bone scan and/or 1 soft tissue metastasis on computed tomography/magnetic resonance imaging (CT/MRI)\n* Participants who have not undergone bilateral orchiectomy must continue luteinizing-hormone-releasing hormone (LHRH) agonists/antagonists throughout the study.\n* Have adequate organ function.\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) inhibitors or darolutamide.\n* Prior systemic therapy for metastatic castration-resistant prostate cancer(mCRPC) with cytotoxic chemotherapy, PARP inhibitors, novel hormonal agents (NHAs) (enzalutamide, apalutamide, and abiraterone), and radiopharmaceuticals.\n* Serious preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study.\n* Clinically significant heart disease as evidenced by myocardial infarction, arterial thrombotic events, severe or unstable angina, or congestive heart failure (New York Heart Association Class III or IV) within 6 months of assignment to treatment.",
    "miscellaneous_criteria": ""
}